Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Clinical Study to Compare and Evaluate the Pharmacokinetics and Safety of Orally Administered Vorolanib Tablets in Participants With Mild (Child-Pugh A) or Moderate (Child-Pugh B) Hepatic Impairment and Participants With Normal Hepatic Function

NCT07809802 is registered in ClinicalTrials.gov with Betta Pharmaceuticals Co., Ltd. as lead sponsor.

NCT NCT07809802
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07809802 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Clinical Study to Compare and Evaluate the Pharmacokinetics and Safety of Orally Administered Vorolanib Tablets in Participants With Mild (Child-Pugh A) or Moderate (Child-Pugh B) Hepatic Impairment and Participants With Normal Hepatic Function
Lead sponsor
Betta Pharmaceuticals Co., Ltd.
Phase
Phase 1
Overall status
Recruiting
Start date
September 30, 2026
Completion date
June 30, 2027
Enrollment
36 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatic impairment (hi)